Stimwave Technologies Places Hold on Commercialization of Product Line in Australia

Stimwave Technologies Incorporation is a known private medical device company that focuses on providing clients with services that majors in the development, manufacture, and commercialization of wirelessly powered, injectable, micro technology neurostimulators, thereby providing patients with a convenient, safe, minimally invasive, and highly cost-effective pain management solution that is easily incorporated into their daily lives.

The company recently announced a hold to the commercialization of its products line in Australia. With reference to the announcement, this is done in a bid to wait until all its products are fully legalized in the country in other to ensure a smooth passage of its products for the Australian population.

A range of these Stimwave product offerings include the Freedom SCS System and the StimQ PNS System, which provide a safe alternative approach to neuromodulation therapy, reducing the risks associated with Implantable Pulse Generators (IPGs) that contain lithium-ion batteries. IPGs require replacement of batteries that deplete, fail, or potentially cause significant risk to the patient.

Without these products, the Stimwave offering is deficient for many of the patient population and it is not in the best interest of Stimwave to continue serving this market until such a time the full product suite can be utilized,” said Laura Perryman, Founder and CEO of Stimwave.

The Freedom SCS System has been legally marketed in the European Union since 2013, United States since 2014, and Australia since 2014. The StimQ PNS System has been legally marketed in the European Union since 2016, and United States since 2015. Post market experience with the Freedom SCS System and StimQ PNS System in approved markets has affirmed the safety and effectiveness of this product for treating chronic pain throughout the body.